Physician profile
Wei Luo
NPI 1528659836
$3,659.30
in general payments reported to CMS, 2019-2025
26 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $787 · 2023: $649 · 2024: $581 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $244.12 | 2022-2025 | |
| Amgen INC. | $243.92 | 2025 | Evenity, Tepezza |
| Gilead Sciences, INC. | $234.23 | 2025 | Epclusa, Yeztugo |
| Teva Pharmaceuticals USA, INC. | $216.42 | 2024-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $209.46 | 2022-2023 | |
| Glaxosmithkline, LLC. | $205.65 | 2022-2025 | Benlysta |
| Alnylam Pharmaceuticals INC. | $194.82 | 2023 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $184.16 | 2022-2024 | Airsupra |
| Pfizer INC. | $165.35 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $160.39 | 2022 | |
| Novo Nordisk INC | $150.52 | 2022-2023 | Wegovy |
| Medtronic, INC. | $143.62 | 2023-2025 | Interstim, Intellis Adaptivestim |
| Kestra Medical Technology Services, INC. | $136.95 | 2024 | Assure Wcd |
| Scynexis, INC. | $126.31 | 2021 | |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $123.77 | 2022 | |
| Jazz Pharmaceuticals INC. | $121.89 | 2024 | |
| Genzyme Corporation | $115.64 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.80 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $95.04 | 2025 | Auvelity |
| Corcept Therapeutics | $92.92 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $72.95 | 2023 | |
| Boston Scientific Corporation | $65.66 | 2022 | |
| Neurocrine Biosciences, INC. | $49.02 | 2025 | |
| Molnlycke Health Care US, LLC | $45.63 | 2023 | Mepilex Border Sacrum, Mepilex Border Flex, Mepilex |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.